Please login to the form below
small cell lung cancer
This page shows the latest small cell lung cancer news and features for those working in and with pharma, biotech and healthcare.
GSK partners with iTeos Therapeutics on next-gen immuno-oncology drug
Based on the underlying science, we believe that combinations of a PD-1, TIGIT, CD96 and PVRIG inhibitor could become transformative medicines for many patients with cancer,” he added. ... the treatment of patients with metastatic non-small cell lung
Latest news
-
AZ’s Tagrisso approved for EGFR-positive NSCLC in the EU
AstraZeneca’s (AZ) third-generation EGFR tyrosine kinase inhibitor (TKI) Tagrisso has been approved to treat early-stage EGFR mutated non-small cell lung cancer (NSCLC) in the EU. ... study. In a statement, AZ said that approximately a fifth of global
-
BeiGene, Novartis' tislelizumab report promising topline results in nasopharyngeal cancer
NPC is a squamous cell carcinoma arising from the epithelial cells of the nasopharynx, with an estimated 60, 558 new cases of this cancer type in China in 2018 – accounting for ... In April, BeiGene also unveiled results from a key global trial
-
Roche's Tecentriq reduces risk of disease recurrence or death by 34% in some NSCLC patients
Roche’s immunotherapy Tecentriq has shown the first clinical improvement in post-surgery non-small cell lung cancer (NSCLC) although its benefit is limited to certain patients. ... Tecentriq is currently approved for the front-line treatment of small
-
GSK discontinues two feladilimab trials in head and neck cancer
Feladilimab aims to selectively enhance T cell function by stimulating ICOS, a protein found on the surface of certain T cells often found on a number of solid tumours. ... An interim analysis of the EMERGE study found that vopratelimab in combination
-
BeiGene, Novartis’s PD-1 inhibitor tislelizumab hits the mark in second- or third-line NSCLC
in non-small cell lung cancer (NSCLC) at the virtual American Association for Cancer Research (AACR) annual meeting. .
AZ’s Tagrisso approved for EGFR-positive NSCLC in the EU
BeiGene, Novartis' tislelizumab report promising topline results in nasopharyngeal cancer
Roche's Tecentriq reduces risk of disease recurrence or death by 34% in some NSCLC patients
GSK discontinues two feladilimab trials in head and neck cancer
More from news
Approximately 10 fully matching, plus 667 partially matching documents found.
Latest Intelligence
-
The promise of precision medicine
Conditions classified as rare diseases affect a relatively small percentage of people in the world. ... The most promising results seen to date show that genetic information has helped boost the survival rates of those suffering from advanced
-
Successful product commercialisation: what can we learn from the rare disease setting?
With an increasing number of drug trials in crowded markets such as oncology (for example, in non-small cell lung cancer and multiple myeloma), understanding patient needs is not only critical ... For novel therapies (including medicines aimed at rare
-
Unlocking the potential of precision medicine in oncology
Targeted therapies. Furthermore, by following a similar trajectory in the treatment of non-small cell lung cancer (NSCLC), where we are studying specific alterations in the epidermal growth factor receptor (EGFR), ... We are following a similar approach
-
BiTE* platform and the evolution toward off-the-shelf immuno-oncology approaches
Amgen brought the first approved BiTE molecule targeting CD19 to patients and we continue to pioneer the bispecific space by exploring this technology across solid tumors, such as small-cell lung ... the other is designed to engage with any
-
Guiding star of science leads AstraZeneca to breakthrough in child tumour therapy
targets of small cell lung cancer and melanoma in adults, while its licensing became embroiled in a royalties dispute. ... The NF1 gene provides instructions to make neurofibromin which acts as a tumour suppressant but if it mutates, tumour cell growth
The promise of precision medicine
Successful product commercialisation: what can we learn from the rare disease setting?
Unlocking the potential of precision medicine in oncology
BiTE* platform and the evolution toward off-the-shelf immuno-oncology approaches
Guiding star of science leads AstraZeneca to breakthrough in child tumour therapy
More from intelligence
Approximately 0 fully matching, plus 28 partially matching documents found.
Latest appointments
-
Merck’s R&D chief Roger Perlmutter heads for the exit as Dean Li takes the helm
newly-diagnosed non-small cell lung cancer (NSCLC) patients.
-
Merck appoints ex-Pfizer exec as global head of oncology
In this role, she will be responsible for defining the pharmaceutical company's integrated global oncology strategies and delivering therapeutic launches, including the commercial launch of Avelumab, a non-small cell ... lung cancer therapy, which is
-
BIND Therapeutics appoints Andrew Hirsch as permanent CEO
Its lead compound, BIND-014, is currently in phase II clinical trials for KRAS-mutant and squamous histology non-small cell lung cancer.
-
Charles Morris appointed chief development officer at ImmunoGen
Dr Morris, who joins from Allos Therapeutics, will oversee all aspects of product development for the US cancer-focused biotech. ... Its pipeline includes the investigational compounds IMGN901 - in phase II testing for the treatment of small-cell lung
-
Axelar appoints Carl Harald Janson as CEO
Takes control as company prepares to take novel cancer drug to proof-of-concept. ... The biotech is currently running a randomised phase II clinical trial with AXL1717 in non-small cell lung cancer (NSCLC) patients, while a first-in-man phase I/II
Merck’s R&D chief Roger Perlmutter heads for the exit as Dean Li takes the helm
Merck appoints ex-Pfizer exec as global head of oncology
BIND Therapeutics appoints Andrew Hirsch as permanent CEO
Charles Morris appointed chief development officer at ImmunoGen
More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest from PMHub
-
The heavy toll of COVID-19 on cancer patients
During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. ... The therapy works predominantly on non-small cell lung cancer. The NHS has also rolled out four chemo-buses which allowed patients to take part in therapy
-
Delphi Technique Virtual Co-creation: A Customer Story
The client’s main objectives were to:. Determine the current barriers to biomarker testing and biomarker-based treatment for non-small cell lung cancer (NSCLC), including differences in regional access and
-
The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments
Lenalidomide. Revlimid. Celgene. Thalidomide. Thalomid. Celgene. Melphalan. Multiple brands. -. Erlotinib. Tarceva. Genentech. Front-line treatment of EGFR mutation positive advanced non-small cell lung cancer. ... Non-small cell lung cancer treatments,
-
Therapy Watch expands oncology and IBD portfolios
Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer ... PCa), Renal Cell Carcinoma (RCC) and
-
Therapy Watch expands its oncology portfolio
This month Therapy Watch Oncology will be expanding its portfolio with the addition of Squamous Cell Carcinoma of the Head and Neck (SCCHN). ... Therapy Watch SCCHN is part of a wider portfolio which covers Chronic Lymphocytic Leukaemia (CLL),
More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Client Services Director, Patient Engagement & Solutions, Lo...
-
Highly competitive salary
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
-
Publications Director
-
Competitive Salary
-
Senior Account Manager
-
Salary TBC
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Group Account Director, Patient Engagement & Solutions, Lond...
-
Highly competitive salary
- Senior Medical Writer, Rare diseases, Medical Communications age...
-
Highly competitive salary
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
- Account Director, Publications, Opthalmology, Medical Communicat...
-
Highly competitive salary
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
-
Planner
-
Salary TBC
- Senior Account Director, Publications, Women’s health, Medical C...
-
Highly competitive salary
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
- Senior Account Director, Publications, Opthalmology, Medical Com...
-
Highly competitive salary
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- Pfizer/BioNTech, AZ vaccines effective against Delta COVID-19 variant after two doses
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Novartis highlights potential of its radioligand therapy in prostate cancer at ASCO
- Disappointing results from CureVac’s COVID-19 vaccine as phase 2/3 study shows only 47% efficacy
- Sanofi’s C1s inhibitor sutimlimab hits the mark in late-stage CAD study
- AZ, Pfizer/BioNTech COVID-19 vaccines 'highly effective' against Indian variant
- Court rules on AZ and EU’s COVID-19 vaccine dispute
- BMS and Eisai to collaborate in deal worth up to $3.1bn
- US announces $3bn funding boost for antiviral COVID-19 treatments
- Biogen doses first patient in phase 3 systemic lupus erythematosus study
- Kite partners with Shoreline Biosciences to develop allogeneic cell therapies
- ‘Funny’, ha ha: how neurodiverse comedy can help us understand each other
- BeiGene’s reveals positive data for Brukinsa in head-to-head Imbruvica trial
- Merck signs $1.2bn supply deal with US government for Molnupiravir
- AZ, Pfizer/BioNTech COVID-19 vaccines 'highly effective' against Indian variant
- Sanofi, GSK begin enrolment for phase 3 COVID-19 vaccine study
- UK launches subscription-style payment pilot to incentivise pharma antibiotics R&D
- Sense of belonging
PMHub
BOLDSCIENCE
We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...
Latest intelligence
- How early-stage clinical research is facilitating the new wave of personalised medicines
- By Jorg Taubel...
- Patient diversity in clinical trials needs to be centre stage
- By Danny Buckland...
- Why empathy in digital patient recruitment is vital
- This is where empathy mapping can be incredibly effective....
